isosulfanblue.mylan.comlsosulfan Blue Injection 1%| Mylan

PRESCRIBING INFORMATION IMPORTANT SAFETY INFORMATION ORDERING INFORMATION This site is for US Healthcare Professionals This site is for US Healthcare Professionals PRESCRIBING INFORMATION IMPORTANT SAFETY INFORMATION Why consider Isosulfan Blue? ADMINISTRATION ORDERING INFORMATION This site is for US Healthcare Professionals This site is for US Healthcare Professionals Why consider Isosulfan Blue? ADMINISTRATION When you trust the only commercially available FDA-approved blue dye indicated for sentinel lymph node mapping, the results are illuminating! INDICATION: lsosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities. π Isosulfan Blue is an important part of Mylan’s growing oncology portfolio Mylan now offers more than 40 therapies, from treatments for solid tumors and cancers of the blood to supportive care. ‡ Learn more about Mylan's full health systems product portfolio Isosulfan Blue injection 1% has been used in sentinel lymph node mapping for more than 30 years. † Isosulfan Blue injection has exceptionally high purity of at least 99%. ¥ Efficacy profile highlights Approximately 500,000 sentinel lymph node mapping procedures are performed in the United States every year. ‡ Isosulfan Blue Injection 1% offers clinicians a ready-to-inject blue dye, with no reconstitution or dilution required prior to administration. π Administration highlights Isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) mL into three (3) interdigital spaces of each extremity per study. A maximum dose of 3 mL (30 mg) isosulfan blue is, therefore, injected. Overall incidence of hypersensitivity reaction in approximately 2% of patients, including life-threatening anaphylactic reactions. π In a study of 543 patients, <1% receiving Isosulfan Blue experienced an allergic reaction, all of whom recovered within 1 hour with no or minimal symptomatic therapy. § Trained personnel should be available to carry out emergency care, including resuscitation, for at least 60 minutes after administration. π Adverse skin reactions include transient or long-term blue coloration. π No drug interactions have been reported in the full Prescribing Information. π Postmarketing cases report drug interactions with chronic preoperative use of angiotensin-converting enzyme inhibitors and angiotensin receptor blocking agents. π Please see Indications and Important Safety Information References † Lymphazurin is a registered trademark of Covidien LP, but this product is not currently commercially available. ‡ IMS Health Procedure Data (December 2015). § In the study by Hirsch and colleagues, the 543 patients who received Isosulfan Blue (Lymphazurin ® ) were divided into 3 groups according to the clinical indication for the lymphangiogram. Group 1 (n=508) included patients with possible lymph node involvement by primary or secondary malignancy; group 2 (n=28) included patients with possible primary lymphatic disease; and group 3 (n=7) included patients with chyluria, chylous ascites or chylothorax. Inadequate identification of lymphatics occurred in 5, 9 and 0 patients in groups 1, 2 and 3, respectively. (Hirsch JI, Tisnado J, Cho SR, Beachley MC. Use of isosulfan blue for identification of lymphatic vessels: experimental and clinical evaluation. AJR Am J Roentgenol. 1982;139(6):1061-1064). ¥ Purity of the active pharmaceutical ingredient as determined by high-performance liquid chromatography (HPLC). π Isosulfan Blue 1% injection [package insert]. Rockford, IL: Mylan Institutional LLC; 2017. You are now leaving this Mylan affiliate site. Mylan is not responsible for the content of the site you are about to visit. Cancel Continue Mylan.com ©2018 Mylan Institutional ISB-2018-0008 The Mylan logo is a registered trademark of Mylan Inc. Privacy Statement Copyright and Legal Disclaimer Contact Us MORE LESS IMPORTANT SAFETY INFORMATION INDICATION lsosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymph edema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities. -- Life-threatening anaphylactic reactions have occurred after isosulfan blue injection 1% administration. Reactions are more likely to occur in patients with a history of bronchial asthma, allergies, drug reactions or previous reactions to triphenylmethane dyes or related compounds. Monitor patients closely for at least 60 minutes after administration and have trained personnel available to administer emergency care including resuscitation. Do not mix isosulfan blue with local anesthetics in the same syringe as this results in immediate precipitation. lsosulfan blue interferes with measurements of oxygen saturation in peripheral blood by pulse oximetry and can cause falsely low readings. The interference effect is maximal at 30 minutes and minimal generally by 4 hours after administration. Arterial blood gas analysis may be needed to verify decreased arterial partial pressure of oxygen. lsosulfan blue injection 1% may also cause falsely elevated readings of methemoglobin by arterial blood gas analyzer. Therefore, cooximetry may be needed to verify methemoglobin level. In post-marketing experience, hypersensitivity reactions have occurred in approximately 2% of patients. Transient or long-term (tattooing) blue coloration has been reported. Click here for full Prescribing Information. INDICATION lsosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymph edema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities....